US · Healthcare · Biotechnology
EPS came in at 0.87 against a street estimate of 0.76 — a beat of 14.5%.
Analysts rate Exelixis Inc a buy (10 buy, 9 hold, 1 sell out of 20) with an average price target of $52.07.
| Fund | Stake |
|---|---|
| BlackRock Inc | 12.26% |
| Renaissance Technologies Corp | 5.46% |
| Farallon Capital Management, L.L.C. | 5.22% |
| AQR Capital Management LLC | 5.21% |
| Vanguard Portfolio Management, LLC | 4.81% |
| Vanguard Capital Management, LLC | 4.48% |
| State Street Corp | 4.10% |
| Fuller & Thaler Asset Management Inc | 3.40% |
| Document | Date |
|---|---|
| Board / officer change · Q2 2026 | 2026-05-29 |
| Quarterly report · Q2 2026 | 2026-05-05 |
| Results announced · Q2 2026 | 2026-05-05 |
| Proxy statement · Q2 2026 | 2026-04-15 |
| Annual report FY2026 | 2026-02-10 |
| Results announced · Q1 2026 | 2026-02-10 |
| Results announced · Q1 2026 | 2026-01-12 |
| Quarterly report · Q4 2025 | 2025-11-04 |
Readable in the app.
| Announcement | Date |
|---|---|
| Board authorizes $750 million stock repurchase program through December 2027 Exelixis, a pharmaceutical company, announced its Q1 2026 financial results on May 5, 2026. While the specific financial numbers aren't detailed in this filing excerpt, the company demonstra | 2026-05-05 |
| Preliminary FY2026 results announced with FY2027 financial guidance provided Exelixis, Inc. announced preliminary unaudited financial results for fiscal year ended January 2, 2026, along with guidance for the next fiscal year (ending January 1, 2027) and a business u | 2026-01-12 |
| Board authorizes $750 million stock repurchase program through December 2026 Exelixis, a biopharmaceutical company, announced its third-quarter 2025 financial results on November 4, 2025. While the 8-K filing itself doesn't include detailed financial figures (they're | 2025-11-04 |
Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Exelixis Inc — free to start.
Google PlayApp StoreData updated 2026-08-05.